Transgene S.A. TNG.PA PAR · Healthcare · France
0.73 € +0.27% +0.00 €
Summary
32 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: 4.25M € against 2.18M €.
What to watch
- Revenue fell by 46% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue fell by 30% a year over 5 years. Over the last 3 years it fell by 46% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail